

PDF hosted at the Radboud Repository of the Radboud University Nijmegen

The following full text is a publisher's version.

For additional information about this publication click this link.

<http://hdl.handle.net/2066/22200>

Please be advised that this information was generated on 2019-02-19 and may be subject to change.

5. Hutchinson RJ, Shapiro SA, Raney RB. Elevated parathyroid hormone levels in association with rhabdomyosarcoma. *J Pediatr* 1978; 92: 780-1.
6. Suzuki Y, Yamada S. Ascites sarcoma 180, an animal model of humoral hypercalcemia of malignancy, produces a factor (s) exhibiting potent bone resorbing activity without any parathyroid hormone-like activity. *Bone Min* 1991; 14: 1-13.

Adjuvant chemo-hormonal therapy with cyclophosphamide, doxorubicin and 5-fluorouracil (CAF) with or without medroxyprogesterone acetate for node-positive cancer patients. Update at 7-year follow-up

The Comprehensive Cancer Center Limburg trial 82-01 is a prospective randomized investigation of the value of the addition of high-dose medroxyprogesterone acetate (MPA) to CAF chemotherapy in patients with node-positive (N+) operable breast cancer (T₁₋₃, N₁). The results of 408 evaluable patients, after a median follow-up of 42 months, have been published in *Annals of Oncology* [1] and can be summarized as follows: high dose MPA ameliorates CAF side effects and reduces the risk of metastatic disease in elderly breast cancer patients. Patients ≥ 60 years benefitted most from MPA treatment, in particular if freedom from distant metastasis was taken as endpoint ($p = 0.02$). Overall survival (OS) showed a significant advantage in patients ≥ 55 years ($p = 0.002$). In this letter we report the updated results after a follow-up of 7 years.

After a median follow-up of 84 months the conclusions of the study remain unchanged. No differences in disease-free survival (DFS), distant-metastasis-free survival or OS were found for the patients as a whole (p -values were 0.12, 0.12 and 0.18, respectively). OS curves of all patients whether treated or not with MPA are shown in Fig. 1. Subset analysis revealed a significantly better DFS for the patient group aged between 40 and 60 years than for the group ≤ 40 or > 60 years ($p = 0.002$). This difference is MPA treatment independent.

Patients ≥ 60 years showed a significantly longer DFS and OS when MPA was added to CAF chemotherapy (p -values 0.05 and 0.008, respectively) (Fig. 2).

By contrast, in the subgroup of patients < 40 years, the addition of MPA to chemotherapy proved detrimental: the relative risk (RR) for relapse of breast cancer was 1.6 versus 1.1 for patients with and without MPA, respectively, while the RR in the group ≥ 60 years was lower (0.7 vs. 1.0), in favor of the MPA-treated group.

In conclusion, this trial suggests a beneficial effect of MPA in combination with chemotherapy in elderly patients (≥ 60 years). The beneficial effect may in part be explained by higher estrogen receptor (ER) levels in elderly breast cancer patients. In young breast cancer patients (≤ 40 years) MPA added to adjuvant chemotherapy has a detrimental effect, possibly caused by its protective effect on ovarian function during CAF chemotherapy [2], which prevents CAF chemotherapy-induced ovarian ablation. An alternative explanation may be that MPA reduces the cellular ER and PgR content in breast cancer cell lines [3]. This down-regulation of ER content in pre-menopausal breast cancer patients could have a

Overall Survival: Kaplan-Meier Curves for CAF versus CAF+MPA with 95% Pointwise Confidence Intervals




Fig. 1. Overall Survival (OS) curve for all node-positive patients in both treatment arms. No statistically significant differences between the two treatment arms ($p = 0.12$). For both survival curves 95% confidence bounds are drawn.

Overall Survival in Patients Older than 60 Years CAF versus CAF+MPA, with 95% Pointwise Confidence Intervals




Fig. 2. Overall Survival (OS) curve for both treatment arms in patients ≥ 60 and ≤ 70 years. Differences in favor of the CAF + MPA treatment arm ($p = 0.008$). For both survival curves 95% simultaneous confidence bounds are drawn.

negative influence of endogenous estrogen on the tumor-cell cycle (lower percentage of tumor cells in the proliferative phase) causing a reduced effect of adjuvant chemotherapy on tumor cells in premenopausal patients.

The previously described bone marrow protective effect of MPA [1] is supported by two recent studies demonstrating in vitro that MPA causes a cell-cycle arrest of hematopoietic precursors which protects them from the toxicity of chemotherapy [4], and in vivo that MPA induces a mitotic arrest in hematopoietic stem cells [5].

The combination of MPA and chemotherapy deserves further exploration in postmenopausal breast cancer patients.

P. Hupperets,¹ J. Wils,¹ L. Volovics,¹ L. Schouten,¹ M. Fickers,¹ H. Bron,¹ H. Schouten,¹ J. Jager,¹ J. de Jong,¹ L. Beex,² H. Hillen¹ & G. Blijham³

¹Breast Cancer Study Group of the Comprehensive Cancer Center Limburg, Academic Hospital Maastricht, 6202 AZ Maastricht; ²Department of Internal Medicine,

Section of Endocrinology, Academic Hospital Nijmegen; ³Department of Internal Medicine, Academic Hospital Utrecht, The Netherlands

References

1. Hupperets PSGJ, Wils J, Volovics J et al. Adjuvant chemohormonal therapy with cyclophosphamide, doxorubicin and 5-fluorouracil (CAF) with or without medroxyprogesterone acetate for node-positive breast cancer patients. *Ann Oncol* 1993; 4: 295-301.
2. Familiari G, Caggiati A, Nottola SA et al. Ultrastructure of human ovarian primordial follicles after combination chemotherapy for Hodgkin's disease. *Hum Reprod* 1993; 8 (2): 2080-7.
3. Classen S, Possinger K, Pelka-Fleischer R et al. Effect of onapristone and medroxyprogesterone acetate on the proliferation and hormone receptor concentration of human breast cancer cells. *J Steroid Biochem Mol Biol* 1993; 34(4): 315-9.
4. Quesada AR, Jimeno JM, Marquez G et al. Cell cycle arrest of human hematopoietic progenitors induced by medroxyprogesterone acetate. *Exp Hematol* 1993; 21 (11): 1413-8.
5. Amadori D, Frassinetti GL, Flamini E et al. Clinical and laboratory evaluation of the myeloprotective effect of medroxyprogesterone acetate in head and neck cancer. *Eur J Cancer* 1992; 28A (8-9): 1331-4.